Research

I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.

I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.

Other Activities

• Fellow of the Academy of Medical Sciences
• Fellow of the Royal Society
• Science Strategy Committee member for Breast Cancer Now
• Research Strategy Group member for Prostate Cancer UK

Major Funding

• 2018-2023- CRUK, Catalyst
• 2017-2020- Barts Charity, Preventative Neurology
• 2014-2019- CRUK, Cancer Prevention
• 2007-2019- CRUK, IBIS II

Recent Publications

Obesity at age 20 and weight gain during adulthood increase risk of total and premature all-cause mortality: findings from women attending breast screening in Manchester Pegington M, Harvie M, Harkness EF et al. BMC Women's Health (2023) 23(7)

Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States. Cuzick J, Adcock R, Kinney W et al. Int J Cancer (2023) (2)
https://www.ncbi.nlm.nih.gov/pubmed/36946690

Abstract PD14-01: PD14-01 A model to assess the utility of risk-based screening algorithms Atakpa EC, Cuzick J, Duffy SW et al. Cancer Research (2023) 83(10) pd14-01-pd14-01

The importance of long-term follow up of participants in clinical trials Cuzick J British Journal of Cancer (2023) 128(7) 432-438

A case–control study to evaluate the impact of the breast screening programme on breast cancer incidence in England Blyuss O, Dibden A, Massat NJ et al. Cancer Medicine (2023) 12(7) 1878-1887

Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets Berney DM, Finnegan K, Chu K et al. Histopathology (2023) (7)

Interpreting the results of noninferiority trials—a review Cuzick J, Sasieni P British Journal of Cancer (2022) 127(7) 1755-1759

39. Associations between somatically altered genes and recurrence outcomes in estrogen receptor positive breast cancer Anurag M, Chu K, Li B et al. Cancer Genetics (2022) 268(10) 13

Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing. Dinneen E, Shaw GL, Kealy R et al. BJUI Compass (2022) 3(2) 458-465
https://www.ncbi.nlm.nih.gov/pubmed/36267207

DNA methylation testing with S5 for triage of high-risk HPV positive women Adcock R, Nedjai B, Lorincz AT et al. International Journal of Cancer (2022) 151(7) 993-1004

Biography

I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.

I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.